Z-Ala-Ala-Asp-CMK
Based on 2 publication(s) in Google Scholar
Z-Ala-Ala-Asp-CMK (Z-AAD-CMK) is a selective granzyme B inhibitor. By binding to the active site of granzyme B, Z-Ala-Ala-Asp-CMK blocks its proteolytic function. Z-Ala-Ala-Asp-CMK has anti-inflammatory activity and can be used in the research of inflammatory diseases and cancer.
For research use only. We do not sell to patients.
- Purity: 99.08%
- CAS No.: 183284-21-1
- Formula: C19H24ClN3O7
- Molecular Weight:441.86
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Z-Ala-Ala-Asp-CMK
MoreAll Caspase Isoforms
More
Biological Activity
|
Caspase 3 |
Z-Ala-Ala-Asp-CMK (10 ng/mL; 72 h) inhibits granzyme B-induced IL-18 activation and IFN-γ secretion in co-culture systems of normal human keratinocytes and CD8+ T cells[1].
Z-Ala-Ala-Asp-CMK (50 μM; 18 h) reduces DNA fragmentation, inhibits caspase-3 activity and ROS production in co-culture systems of OSC-3 cells pretreated with anticancer drugs or γ-rays and LAK cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 183284-21-1
-
Appearance Solid
-
Molecular Weight 441.86
-
Formula C19H24ClN3O7
-
Color White to off-white
-
Synonyms
Z-AAD-CMK
-
Sequence
Z-Ala-Ala-Asp-CMK
-
Sequence Shortening
Z-AAD-CMK
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Autophagy
NK cell-derived GZMB (granzyme B) suppresses glioblastoma radioresistance by blocking SDC1-mediated autophagosome maturation. [Abstract]2026 Jan 9:1-22. PMID: 41378763 -
Adv Healthc Mater
Self-Assembling Multi-Antigen T Cell Hybridizers for Precision Immunotherapy of Multiple Myeloma. [Abstract]2025 Aug 1:e02156. PMID: 40747784
Solvent & Solubility
DMSO : 100 mg/mL (226.32 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.66 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (273 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Youichi Omoto, et al. Granzyme B is a novel interleukin-18 converting enzyme. J Dermatol Sci. 2010 Aug;59(2):129-35. [Content Brief]
[2]. Yamamoto T, et al. Enhanced apoptosis of squamous cell carcinoma cells by interleukin-2-activated cytotoxic lymphocytes combined with radiation and anticancer drugs. Eur J Cancer. 2000 Oct;36(15):2007-17. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2632 mL | 11.3158 mL | 22.6316 mL | 56.5790 mL |
| 5 mM | 0.4526 mL | 2.2632 mL | 4.5263 mL | 11.3158 mL | |
| 10 mM | 0.2263 mL | 1.1316 mL | 2.2632 mL | 5.6579 mL | |
| 15 mM | 0.1509 mL | 0.7544 mL | 1.5088 mL | 3.7719 mL | |
| 20 mM | 0.1132 mL | 0.5658 mL | 1.1316 mL | 2.8290 mL | |
| 25 mM | 0.0905 mL | 0.4526 mL | 0.9053 mL | 2.2632 mL | |
| 30 mM | 0.0754 mL | 0.3772 mL | 0.7544 mL | 1.8860 mL | |
| 40 mM | 0.0566 mL | 0.2829 mL | 0.5658 mL | 1.4145 mL | |
| 50 mM | 0.0453 mL | 0.2263 mL | 0.4526 mL | 1.1316 mL | |
| 60 mM | 0.0377 mL | 0.1886 mL | 0.3772 mL | 0.9430 mL | |
| 80 mM | 0.0283 mL | 0.1414 mL | 0.2829 mL | 0.7072 mL | |
| 100 mM | 0.0226 mL | 0.1132 mL | 0.2263 mL | 0.5658 mL |
Z-Ala-Ala-Asp-CMK Related Classifications
HY-P10004 Related Classifications
Powered by Bioz